Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07079735 · ClinicalTrials.gov registry record · Phase 2
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
A Phase 2 study of Heart Transplant Failure and Rejection and Heart Transplant Infection, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT07079735: Recruiting Phase 2 study of Heart Transplant Failure and Rejection and Heart Transplant Infection, sponsored by Columbia University.
NCT07079735 is a Phase 2 study of Heart Transplant Failure and Rejection and Heart Transplant Infection that is actively recruiting participants, run by Columbia University. The registered enrollment target is 150 participants, below the 181-participant average among 5 other Heart Transplant Failure and Rejection trials with a reported enrollment target (17% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07079735, a Phase 2 study of Heart Transplant Failure and Rejection and Heart Transplant Infection, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
Primary Outcome
Number of patients with leukopenia (white blood cell count \<3000 cells µL)
Conditions Studied
Interventions
- DRUG Letermovir
- DRUG Valganciclovir
Study Locations (2)
New York
- NYP-Weill Cornell - New York
- Columbia University/NYP Milstein Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-09-12 |
| Est. Completion | 2029-01-17 |
| Phase | Phase 2 |
What NCT07079735 shows while recruiting
NCT07079735 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 181-participant average among 5 other Heart Transplant Failure and Rejection trials with a reported enrollment target (17% lower).
The record links to 3 conditions, with Heart Transplant Failure and Rejection appearing as the primary indexed condition, and to 2 interventions - of which Letermovir is the first listed.
NCT07079735 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07079735 about?
NCT07079735 is a clinical study titled "Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant". The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
What is the current status of trial NCT07079735?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-09-12. Estimated completion is 2029-01-17.
What conditions does trial NCT07079735 study?
This clinical trial studies the following conditions: Heart Transplant Failure and Rejection, Heart Transplant Infection, CMV Viremia.
What interventions are being tested in trial NCT07079735?
The interventions under investigation include: Letermovir (DRUG), Valganciclovir (DRUG).
Who is sponsoring clinical trial NCT07079735?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07079735 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Transplant Failure and Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allograft Dysfunction in Heart Transplant
RECRUITING · Phase 4
-
HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
ACTIVE NOT RECRUITING
-
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
ACTIVE NOT RECRUITING · NA
-
Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant
ACTIVE NOT RECRUITING · NA
-
Bioelectrical Impedance Spectroscopy in Heart Transplantation: Tracking Post-Transplant Changes in Body Composition and Correlation With Conventional Preoperative Risk Assessment Modalities
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI